Drug Profile
Research programme: Rett syndrome therapeutics - Melior Discovery/Rett Syndrome Research Trust
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Rett Syndrome Research Trust
- Developer Melior Pharmaceuticals, Inc.
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rett syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rett syndrome in USA
- 01 Apr 2010 Preclinical trials in Rett syndrome in USA (unspecified route)